Amylyx Pharmaceuticals (AMLX) closed at $29.86 on November 12, 2026, down 6.1% from the previous close, on volume of 1,377,066 shares (30-day average 1,311,417).
Data as of November 12, 2026.
12-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 26, 2026 | Calendar Call Spread | 20-Nov : 18-Dec-26 33 C | 388 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 12, 2026. See the 10 largest for 30, 60 and 90 days
Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results
Business Wire (Thu, 5-Nov 7:00 AM ET)
Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek 2026 Featuring Leading PBH Experts
Business Wire (Wed, 4-Nov 9:00 AM ET)
Amylyx sets two November fireside chats with 90-day replays for investors
Market Chameleon (Tue, 3-Nov 4:54 AM ET)
Amylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences
Business Wire (Tue, 3-Nov 9:00 AM ET)
Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026
Business Wire (Mon, 2-Nov 9:00 AM ET)
Business Wire (Tue, 6-Oct 8:00 AM ET)
Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum
Business Wire (Wed, 23-Sep 9:00 AM ET)
Tortugas Neuroscience Announces Appointment of Jim Frates to Board of Directors
Business Wire (Wed, 9-Sep 8:00 AM ET)
Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference
Business Wire (Tue, 8-Sep 9:00 AM ET)
Amylyx Upsizes to $500 Million Public Offering: Targeting Pipeline Growth and Avexitide Launch
Market Chameleon (Thu, 20-Aug 4:14 AM ET)
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
Amylyx Pharmaceuticals trades on the NASDAQ stock market under the symbol AMLX.
As of November 12, 2026, AMLX stock price declined to $29.86 with 1,377,066 million shares trading.
AMLX has a beta of 0.50, meaning it tends to be less sensitive to market movements. AMLX has a correlation of 0.01 to the broad based SPY ETF.
AMLX has a market cap of $3.32 billion. This is considered a Mid Cap stock.
Last quarter Amylyx Pharmaceuticals reported $0 in Revenue and -$.38 earnings per share. This fell short of revenue expectation by $-41,600 and missed earnings estimates by -$.01.
In the last 3 years, AMLX traded as high as $41.14 and as low as $1.58.
The top ETF exchange traded funds that AMLX belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.
AMLX has outperformed the market in the last year with a price return of +142.2% while the SPY ETF gained +11.9%. AMLX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +27.9% and +4.1%, respectively, while the SPY returned -1.7% and -1.6%, respectively.
AMLX support price is $30.78 and resistance is $32.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AMLX shares will trade within this expected range on the day.
